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Chlamydia trachomatis polymorphic membrane proteins (Pmps) may increase genital tract inﬂammation and play a role in
virulence. Antibody levels for PmpA, PmpD, and PmpI, measured in densitometric units, were assessed among a pilot sample
of 40 C. trachomatis-infected women with mild-to-moderate clinical PID. Women who expressed antibodies to PmpA were less
likely to achieve pregnancy (40.0% versus 85.7%; P = 0.042) and less likely to have a live birth (0.0% versus 80.0%; P = 0.005)
compared to women who did not express antibody to PmpA. Women who expressed antibodies to PmpI were more likely to have
upper genital tract infection (61.5% versus 20.0%; P = 0.026). However, seropositivity to PmpI and PmpD did not modify the
risk of reproductive sequelae or inﬂammation. Seropositivity to chlamydial PmpA may represent a biomarker of increased risk of
sequelae secondary to infection with C. trachomatis.
1.Introduction
Chlamydia trachomatis is the most common bacterial sexu-
allytransmitted infectionin theUnited States[1]. Inwomen,
C. trachomatis can ascend from the endocervix to the upper
genital tract and cause pelvic inﬂammatory disease (PID)
and serious reproductive morbidity including infertility
and ectopic pregnancy [2]. However, rates of progression
vary and 80% or more of women with chlamydia do not
develop PID [1]. Some women clear chlamydial infection
without tissue damage, while in some cases C. trachomatis
induces a chronic low-grade infection [3]. This may lead
to persistent inﬂammation of the upper genital tract caus-
ing long-term reproductive sequelae. The pathogenesis of
C. trachomatis diseaseisnotwell-understood,andpathogen-
speciﬁc virulence factors that may contribute to variability in
thecourseandoutcomeofinfectionhavenotbeenidentiﬁed.
Nine surface-exposed C. trachomatis polymorphic mem-
brane proteins (Pmps) are encoded via a multigene family
yielding PmpA to PmpI [4]. Pmps represent 13.6% of the
coding capacity of the C. trachomatis genome [4], suggesting
they have a critical role in biology and virulence [5, 6].
However, the role of Pmps in chlamydial virulence is not well
understood. PmpD is a species-common, pan-neutralizing
antigenhypothesized toholdpotential asavaccinecandidate
[6]. Thus, the development of high titers of antibody to
PmpD might protect from infection or disease. On the other
hand, Chlamydia pneumoniae Pmps have been shown to
induce proinﬂammatory mediators in infected host cells,
demonstratingthepotentialfortheseproteinstoplayadirect
role in pathogenesis [7, 8]. All nine Pmps are expressed on
the surface of chlamydial elementary bodies (EB) and C.
trachomatis-infected patients can produce antibodies to each
Pmp subtype [9]. However, antibody proﬁles vary among2 Infectious Diseases in Obstetrics and Gynecology
C. trachomatis-infected patients [5]. In addition, compara-
tive genomics has revealed genetic variation and rearrange-
ments among pmp gene families in diﬀerent strains and
isolates [5, 9]. This suggests that immune pressure leads
to antigenic variation in these surface-exposed proteins [5,
9], a further indication that these proteins have a role in
chlamydial virulence.
Pmps may be involved in virulence, but very little is
known about their role in the development of PID and
adverse reproductive sequelae. Tan et al. examined variation
in Pmp-speciﬁc antibody responses in four distinct patient
populations, demonstrating that women with PID had
signiﬁcantly higher reactivity to PmpB and PmpI compared
to adolescent females with lower genital tract infection [5].
These data may reﬂect a role for these speciﬁc Pmps in
inﬂammation,orsimplythatwomenwithPIDhadsustained
increased exposure due to repeated or chronic infection.
In a separate study, Tan et al. found that Pmps exhibit
on/oﬀ switching in vitro which enables independent expres-
sion of each Pmp [9]. PmpA, PmpD, and PmpI had very
low “oﬀ” frequencies of 0.5–1%, suggesting that expression
of these Pmps provides an in vitro phenotypic advantage
[9]. This may or may not translate into enhanced in vivo
virulence. The high “on” frequencies of PmpD and PmpI
correlate with the fact that anti-PmpD and -PmpI antibodies
are commonly detected in C. trachomatis-infected patients.
However, despite the high “on” frequency of PmpA, anti-
PmpA antibodies are relatively rare. Further research from
this group found that Pmp transcriptional units are dif-
ferentially expressed during chlamydial development [10].
In addition, Pmp expression was altered under penicillin-
induced stress, except for the expression of PmpA, PmpD,
andPmpI,whichremainedsteady[10].Takentogether,these
data suggest an importance for PmpA, PmpD, and PmpI in
chlamydial pathogenesis. However, the role of these Pmps
in chlamydial PID has never been examined in humans.
In order to examine the role of PmpA, PmpD, and PmpI
in chlamydial pathogenesis, we conducted a pilot study to
determine if antibody responses speciﬁc for these Pmps were
associated with parameters of inﬂammation or sequelae in a
group of women with documented C. trachomatis PID.
2. Methods
This study utilized data from the PID evaluation and clinical
health (PEACH) study. This was the ﬁrst randomized clinical
trial to compare inpatient and outpatient treatment in
preventinglong-termcomplicationsamong831womenwith
mild-to-moderate PID. The methods of subject recruitment,
data collection, and followup have been reported elsewhere
[11]. Brieﬂy, between March 1996 and February 1999,
women aged 14–37 years were recruited from emergency
departments, obstetrics and gynecology clinics, sexually
transmitted disease clinics, and private practices at 7 primary
and 6 secondary sites throughout the eastern, southern, and
central regions of the United States. Women who had sus-
pected PID and gave informed consent were eligible for the
PEACHstudy.Womenwereenrolledonthebasisofclinically
generalizable criteria for suspected PID. Eligibility included
a history of pelvic discomfort for less than 30 days, ﬁndings
of pelvic organ tenderness (uterine or adnexal) on bimanual
examination,andleukorrheaand/ormucopurulentcervicitis
and/or untreated but documented gonococcal or chlamydial
cervicitis. The University of Pittsburgh Institutional Review
Board approved the study.
A total of 2941 women were screened for study entry, of
those 346 (11.8%) did not meet the clinical inclusion criteria
for randomization. Women were additionally excluded if
theywerepregnant(n=141,4.8%);hadtakenantimicrobials
within the past 7 days (n=248, 8.4%); had a history of hys-
terectomyorbilateralsalpingectomy(n = 248,8.4%);hadan
abortion, delivery, or gynecologic surgery within the past 14
days (n=51, 1.7%); had a suspected tubo-ovarian abscess or
other condition requiring surgery (n = 191,6.5%); had an
allergy to the study medications (n=163, 5.5%); were home-
less (n = 29, 1%); or had vomiting after a trial of antiemetic
treatment (n = 11, 0.4%). A total of 831 were enrolled and
were contacted at least once after randomization. Our
analysis included a pilot sample of 40 C. trachomatis-positive
women, whose serum samples were previously analyzed for
Pmp antibodies [5]. All sera were collected at baseline.
Women were randomized to either inpatient treatment
of intravenous cefoxitin every 6 hours and doxycycline orally
twice a day for 14 days; or outpatient treatment consisting
of a single intramuscular injection of cefoxitin and oral
doxycycline twice a day for 14 days. Because the treatment
modalitywasnotassociatedwithreproductivemorbiditiesin
the PEACH study [12], we do not include them as a covariate
inthisanalysis.Participantswerefollowed-upwithin-person
visitsat5and30daysaftertreatment.Atthe30-dayfollowup,
the gynecological exam was repeated. Telephone followups
were conducted by the study nurses every 3 months during
the ﬁrst year after enrollment and then every 4 months until
June 2004. At that point, information was obtained by self-
report for 69.1% of the cohort, with a mean followup of 84
months.
A pelvic examination and interview were conducted at
the baseline visit. The interview collected information on
reason for visit, brief pain history, demographics, history
of PID/sexually transmitted diseases, sexual and contra-
ceptive history, reproductive decisions, douching history,
pregnancy history, medical and gynecological history, and
lifestyle habits. Followup interviews collected self-reported
information on pelvic pain, pregnancy and births, signs and
symptoms of PID, STDs, contraceptive use, pattern of sexual
intercourse, and health care utilization.
Gynecological examinations were performed at baseline
and 5 and 30 days after treatment. Endometrial biopsy
and cervical swab specimens were obtained for histolog-
ical examination including chlamydial polymerase chain
reaction (PCR) and gonococcal culture. All cultures and
PCR were performed at a central reference laboratory.
For the patients with endometrial biopsies, two reference
pathologists separately evaluated at least one section stained
with hematoxylin and eosin and at least one stained with
methyl green pyronin. A disagreement about the presence
or absence of neutrophils and plasma cells was settled by
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to an agreement. Histological endometritis was based on
a modiﬁcation of the criteria proposed by Kiviat et al.
[13]. Endometritis was deﬁned as the presence of at least
ﬁve neutrophils in the endometrial surface epithelium in
the absence of menstrual endometrium and/or at least two
plasma cells in the endometrial stroma. This deﬁnition has
been found to be the best predictor of upper genital tract
infection plus salpingitis, with a sensitivity of 92% and
speciﬁcity of 87% [13].
Reproductive outcomes were assessed over a mean of
84 months. Measures of fertility included infertility, live
birth,and pregnancy. Other reproductive outcomesincluded
recurrent PID and chronic pelvic pain. Infertility was
determined among women reporting no birth control or
methods considered being unreliable, including withdrawal,
rhythm method, vasectomy, or using the following methods
rarely or occasionally:diaphragm, condoms, spermicidal
foam/cream/jelly/suppositories, or cervical cap. Infertility
was deﬁned by lack of conception despite unprotected inter-
course during 12 or more months of followup. Self-reported
pregnancy was determined by a positive urine/blood test or
physician’s diagnosis among all women in the cohort. Live
birth was determined among all women in the cohort by
self-report during followup. RecurrentPID wasself-reported
and veriﬁed whenever medical records were available (45%
of cohort). Women were considered to have recurrent PID
if they experienced a subsequent episode of PID more than
30 days after the index illness. Chronic pelvic pain was
deﬁned by two or more consecutive reports of pelvic pain
during telephone followup interviews administered through
32months[14].Thistranslatestoapproximately6monthsor
greater duration of pain [14]. Data from at least 2 followup
visits were required to determine chronic pelvic pain.
Pmp antibody levels were previously measured among a
subset of 40 C. trachomatis-positive women who had stored
serumsamplesavailable.Pmpantibodylevelsweremeasured
in densitometric units. These methods have been described
elsewhere[5].Brieﬂy,puriﬁed EBsorpartiallypuriﬁed rPmp
polypeptides (rPmpD-FL and rPmpI-N) were subjected to
sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Amounts of rPmps were standardized by
immunoblot analysis with anti-His tag antibody (1:1,500;
GE Healthcare). Blots were visualized using Molecular
Dynamics Typhoon 9400 imager (Amersham Biosciences,
NJ). Antibody reactivity against the highest molecular-mass
band in each lane was analyzed using Image Quant 5.2 image
analysis software (Molecular Dynamics Sunnyvale, Calif).
Serum response against each rPmp was quantiﬁed by the
volume of the band. Data were normalized against His-tag-
speciﬁc antibody reactivity.
Since PmpA, PmpD, and PmpI are uniquely expressed
and may play a role in chlamydial pathogenesis [9, 10], we
chose to only include these Pmps in our analyses. Our objec-
tive was to determine if markers of inﬂammation or sequelae
diﬀered between women who displayed antibody reactivity
to PmpA, PmpD, or PmpI and those who did not. Both
continuous and binary variables were used. Diﬀerences in
baselinecharacteristicswerecomparedbetweengroupsusing
Chi-square or Fisher’s exact tests and t-test for the normally
distributedcontinuousvariables.Chi-squareorFisher’sexact
tests were also used to compare diﬀerences in the frequency
of inﬂammatory markers (elevated white blood cell count
(WBC), temperature, elevated C-reactive protein (CRP),
bilateral adnexal tenderness, cervicitis, endometritis, upper
genital tract infection (UGTI), erythrocyte sedimentation
rate (ESR)), and reproductive outcomes (infertility, preg-
nancy, live birth, chronic pelvic pain, and recurrent PID)
between groups. We also examined these relationships using
a continuous variable for Pmp antibody response. As the
distributions of PmpA, PmpD, and PmpI were skewed,
nonparametric tests were used.
We also sought to determine if high levels of Pmp anti-
body expression were associated with inﬂammation or
sequelae. After running sensitivity analyses, antibody reac-
tivitygroupsforPmpDandPmpIweredeﬁnedusingmedian
cut-points (high reactivity: PmpD ≥ 0.41; PmpI ≥ 0.89 and
low reactivity: PmpD < 0.41; PmpI < 0.89). Due to the small
number of women who expressed antibodies to PmpA, we
wereunabletoexaminelevelsofantibodyexpression(n = 5).
Logistic regression was used to calculate odds ratios (OR)
and 95% conﬁdence intervals (CI). Cox regression was used
to calculate hazard ratios and 95% CI for time-to-pregnancy
and time-to-recurrent PID. Models were adjusted for age
and race. Additionally, time to pregnancy was adjusted for
history of infertility, which was self-reported at baseline. If
any model had less than 5 in any cell, it was excluded from
regression analysis. All analyses were completed using SAS
V9.2 (Cary, NC).
3. Results
Overall, women in this cohort tended to be less than 25
years of age (85.0%), African American (77.5%), single
(86.8%),andhavingatleastahighschooleducation(60.0%).
At baseline, the majority of women reported abnormal
vaginal discharge (62.5%), had bilateral adnexal tenderness
(80.0%) and mucopurulent cervicitis (65.7%), and had
chlamydia isolated from the cervix only (58.3%). Women
who expressed antibody to PmpI were more likely to smoke
compared to women who did not express PmpI antibody
(56.7% versus 20.0%; P = 0.0411) (Table 1). There were
noothersigniﬁcantdiﬀerencesinimportantbaselinecharac-
teristics between women who expressed antibody to PmpA,
PmpD, or PmpI and women who did not.
Results show that compared to women who did not
express antibody to PmpA, rates of elevated WBC (40.0%
versus 23.5%), increased CRP (66.7% versus 46.2%),
increased ESR (40.0% versus 31.4%), endometritis (100%
versus 60.7%), and UGTI (75.0% versus 46.8%) were
higher among women who expressed antibody to PmpA
(Table 2). However, these diﬀerences did not reach statistical
signiﬁcance.Similarly,therewerenosigniﬁcantdiﬀerencesin
the frequency of infertility, recurrent PID, or chronic pelvic
pain between groups. However, only 40% of women with
antibody reactivity to PmpA achieved pregnancy compared
to 85.7% of women who did not express antibody reactivity
to PmpA (P = 0.042). In addition, none of the women
with antibody reactivity to PmpA had a live birth, while4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Baseline characteristics of women by Pmp antibody expression.
Characteristics
PmpA PmpD PmpI
No
n = 35
Yes
n = 5 P value No
n = 10
Yes
n = 30 P value No
n = 10
Yes
n = 30 P value
Demographics
Age
<25 years 30 (85.7) 4 (80.0) 0.7378 8 (80.0) 26 (86.7) 0.3213 8 (80.0) 26 (86.7) 0.3213
Race/ethnicity African American 27 (77.1) 4 (80.0) 0.8862 8 (80.0) 26 (76.7) 0.3350 8 (80.0) 23 (76.7) 0.3350
Married 4 (12.1) 1 (20.0) 0.6272 1 (10.0) 4 (14.3) 0.4079 1 (10.0) 4 (14.3) 0.4079
Uninsured 11 (33.3) 3 (60.0) 0.0876 6 (60.0) 18 (64.3) 0.2850 6 (60.0) 18 (64.3) 0.2850
Education less than high school 14 (40.0) 2 (40.0) 1.000 2 (20.0) 14 (87.5) 0.1091 2 (20.0) 14 (46.7) 0.1091
Clinical
Neisseria gonorrhoeae 8 (25.8) 2 (50.0) 0.3134 3 (37.5) 7 (25.9) 0.2709 2 (22.2) 8(30.8) 0.3064
Mycoplasma genitalium 3 (12.5) 1 (25.0) 0.3954 1 (25.0) 3 (12.5) 0.3954 1 (16.7) 3 (13.6) 0.4513
Bacterial vaginosis 21 (67.7) 1 (20.0) 0.0584 5 (55.6) 17 (62.9) 0.2800 5 (55.6) 17 (63.0) 0.2800
History of PID 10 (28.6) 1 (20.0) 0.3970 4 (40.0) 7 (23.3) 0.1849 3 (30.0) 8 (26.7) 0.3038
History of chlamydia 15 (45.5) 3 (60.0) 0.3089 4 (44.4) 14 (48.3) 0.7183 5 (55.6) 13 (44.8) 0.4272
aPelvic pain (mean score ± SD) 65 ± 22 75 ± 15 0.3605 69 ± 14 66 ± 23 0.7387 65 ± 16 67 ± 17 0.7810
bDays of pain(mean score ± SD) 8 ± 75 ± 2 0.3238 6 ± 69 ± 7 0.3637 7 ± 78 ± 7 0.7569
Behavior
Current smoker 15 (42.9) 4 (80.0) 0.1237 4 (40.0) 5 (50.0) 0.2481 2 (20.0) 17 (56.7) 0.0411
Drug use 12 (34.3) 2 (40.0) 0.3596 4 (40.0) 10 (33.3) 0.2719 4 (40.0) 10 (33.3) 0.2719
a(meanofcurrentpelvicpainscore,averagepelvicpainscoreandworstpelvicpainscore) ×10; bSelf-reportedtimetotreatmentfollowingonsetofsymptoms.
80% of women without antibody reactivity to PmpA had
a live birth (P = 0.005). When examined as a continuous
variable the results did not diﬀer. Expression of anti-PmpA
antibody was signiﬁcantly increased in women who did not
achieve pregnancy (P = 0.0192) or did not achieve a live
birth (P = 0.0043).
There were no signiﬁcant diﬀerences in inﬂammatory
m a r k e r so rr e p r o d u c t i v es e q u e l a eb e t w e e nw o m e nw h o
displayed antibody reactivity to PmpD and women who did
not (Table 3). Results did not change when an antibody
response to PmpD was considered as a continuous variable.
Results were similar for PmpI (Table 4). However, women
expressing antibody to PmpI were more likely to have
UGTI compared to women who did not express antibody
to PmpI (61.5% versus 20.0%; P = 0.026). Women who
expressed antibody to PmpI were slightly more likely to
have endometritis (72.7% versus 50.0%) although this did
not reach statistical signiﬁcance (P = 0.2096). When PmpI
antibody response was examined as a continuous variable,
the mean expression did not signiﬁcantly diﬀer between
those with UGTI and those without UGTI (P = 0.276).
When levels of antibody expression for PmpD and PmpI
were examined, there were no signiﬁcant diﬀerences in the
frequency of inﬂammatory markers or reproductive sequelae
between high and low antibody reactivity groups. Although
nonsigniﬁcant, women with high PmpD reactivity were
slightly more likely to have an elevated WBC count (33.3%
versus 16.7%), elevated ESR (42.9% versus 21.1%), elevated
CRP (62.5% versus 37.5%), mucopurulent cervicitis (77.8%
versus 52.9%), and endometritis (75.0% versus 56.3%)
compared to women with low PmpD reactivity. Women
with high PmpI reactivity were slightly more likely to
have elevated CRP (55.6% versus 42.9%), bilateral adnexal
tenderness (85.0% versus 75.0%), mucopurulent cervicitis
(72.2% versus 58.8%), endometritis (71.4% versus 61.1%),
and UGTI (58.8% versus 42.1%) compared to women with
low PmpI reactivity although this did not reach statistical
signiﬁcance. Logistic regression also revealed no signiﬁcant
associations.
Similarly, a nonsigniﬁcant decrease in pregnancy rates
(adjusted hazard ratio (AHR) 0.7, 95% CI 0.3–1.6) and
increase in recurrent PID were observed for women with
high PmpD antibody reactivity (AHR 1.3, 95% CI 0.2–8.3)
(Table 5). In contrast, high PmpI antibody reactivity had
minimal eﬀects on sequelae. However, after adjustments,
women with high PmpI antibody reactivity showed a
nonsigniﬁcant trend towards decreased live births (AOR 0.6,
95% CI 0.1–4.0).
4. Discussion
Among women with mild-to-moderate chlamydial PID,
those who expressed antibody to PmpA were less likely
to achieve pregnancy and less likely to report a live birth.
The overall eﬀects of seropositivity for PmpD and PmpI
on inﬂammation and reproductive sequelae were minimal.
However, women who expressed PmpI antibody were more
likely to have UGTI. Trends towards elevated baseline genitalInfectious Diseases in Obstetrics and Gynecology 5
Table 2: Frequency of baseline inﬂammatory markers and reproductive sequelae by PmpA antibody expression.
Inﬂammation and sequelae
PmpA
No
n = 35
Yes
n = 5 P value
Inﬂammation
aElevated temperature (>100.4◦F) 0 (0.0) 1 (25.0) 0.1111
aElevated WBC count (>10,000mm3) 8 (23.5) 2 (40.0) 0.2856
Erythrocyte sedimentation rate (>15mm/hr) 11 (31.4) 2 (40.0) 0.7019
aC-reactive protein (>5mg/dL) 6 (46.2) 2 (66.7) 0.5218
Bilateral adnexal tenderness 28 (80.0) 4 (80.0) 1.000
aMucopurulent cervicitis 20 (66.7) 3 (60.0) 0.7712
Upper genital tract infection 15 (46.7) 3 (75.0) 0.2494
aEndometritis 17 (60.7) 4 (100.0) 0.1664
Reproductive sequelae
Infertility 5 (14.3) 0 (0.0) 0.3663
bLive birth 20 (80.0) 0 (0.0) 0.0053
Pregnancy 30 (85.7) 1 (40.0) 0.0422
bChronic pelvic pain 13 (38.2) 0 (0.0) 0.1142
bRecurrent PID 6 (17.7) 0 (0.0) 0.4122
aWBC data was available for 39 patients, CRP data was available for 16 patients, mucopurulent cervicitis data was available for 35 patients, UGTI data was
available for 36 patients, and endometritis data was available for 32 patients; blive birth data was available for 29 patients; chronic pelvic pain and recurrent
PID data were available for 39 patients.
Table 3: Frequency of baseline inﬂammatory markers and reproductive sequelae by PmpD antibody expression.
Inﬂammation and sequelae
PmpD
No
n = 10
Yes
n = 30 P value
Inﬂammation
aElevated temperature (>100.4◦F) 0 (0.0) 1 (3.7) 0.7500
aElevated WBC count (>10,000mm3) 2 (20.0) 8 (27.6) 0.3038
Erythrocyte sedimentation rate (>15mm/hr) 3 (30.0) 10 (33.3) 0.2996
aC-reactive protein (>5mg/dL) 2 (40.0) 6 (54.6) 0.3590
Bilateral adnexal tenderness 7 (70.0) 25 (83.3) 0.2224
aMucopurulent cervicitis 4 (50.0) 19 (70.4) 0.1862
Upper genital tract infection 4 (50.0) 17 (70.8) 0.1878
aEndometritis 3 (33.3) 15 (55.6) 0.1609
Reproductive sequelae
Infertility 1 (10.0) 4 (13.3) 0.4165
bLive birth 7 (77.8) 13 (65.0) 0.2787
Pregnancy 8 (80.0) 24 (80.0) 1.000
bChronic pelvic pain 4 (44.4) 9 (30.0) 0.2219
bRecurrent PID 2 (22.2) 4 (13.3) 0.3024
aWBC data was available for 39 patients, CRP data was available for 16 patients, mucopurulent cervicitis data was available for 35 patients, UGTI data was
available for 36 patients, and endometritis data was available for 32 patients; b live birth data was available for 29 patients; chronic pelvic pain and recurrent
PID data were available for 39 patients.
tract and systemic inﬂammation, increased reproductive
morbidity, and decreased pregnancy rates were observed
among women with high PmpD antibody reactivity. Simi-
larly, women with high PmpI antibody reactivity displayed
trends towards elevated baseline inﬂammation. However,
these results were nonsigniﬁcant.
The progression to PID following lower genital
C. trachomatis infection varies. Among high-risk groups,
2–4.5% of women with untreated chlamydial infection
will develop PID within 2 weeks, and 19% with treated
chlamydial infection will develop PID within 3 years
[1, 15–18]. Chlamydial virulence proteins may explain6 Infectious Diseases in Obstetrics and Gynecology
Table 4: Frequency of baseline inﬂammatory markers and reproductive sequelae by PmpI antibody expression.
Inﬂammation and sequelae
PmpI
No
n = 10
Yes
n = 30 P value
Inﬂammation
aElevated temperature (>100.4◦F) 0 (0.0) 1 (3.7) 0.7500
aElevated WBC count (>10,000mm3) 2 (20.0) 8 (27.6) 0.3038
Erythrocyte sedimentation rate (>15mm/hr) 3 (30.0) 10 (33.3) 0.2996
aC-reactive protein (>5mg/dL) 2 (66.7) 6 (46.2) 0.4000
Bilateral adnexal tenderness 6 (60.0) 26 (86.7) 0.0748
aMucopurulent cervicitis 5 (62.5) 18 (66.7) 0.3145
Upper genital tract infection 2 (20.0) 16 (61.5) 0.0263
aEndometritis 5 (50.0) 16 (72.7) 0.1457
Reproductive sequelae
Infertility 1 (10.0) 4 (13.3) 0.4165
bLive birth 6 (75.0) 14 (66.7) 0.3251
Pregnancy 8 (80.0) 24 (80.0) 1.000
bChronic pelvic pain 2 (20.0) 11 (37.9) 0.2996
bRecurrent PID 3 (30.0) 3 (10.3) 0.1344
aWBC data was available for 39 patients, CRP data was available for 16 patients, mucopurulent cervicitis data was available for 35 patients, UGTI data was
available for 36 patients, and endometritis data was available for 32 patients; b live birth data was available for 29 patients; chronic pelvic pain and recurrent
PID data were available for 39 patients.
Table 5: Eﬀect of Pmp antibody reactivity on time-to-pregnancy and time-to-recurrent PID.
Subgroup
Pregnancy Recurrent PID
Crude HR (95% CI) aAdjusted HR (95% CI) Crude HR (95% CI) aAdjusted HR (95% CI)
bHigh PmpD (n = 28) 0.7 (0.3–1.3) 0.7 (0.3–1.6) 0.9 (0.2–4.7) 1.3 (0.2–8.3)
cHigh PmpI (n = 23) 1.3 (0.7–2.7) 1.4 (0.7–3.0) 0.6 (0.1–3.0) 0.7 (0.1–5.3)
aModels were adjusted for age, race, and models predicting infertility, pregnancy, and live birth were additionally adjusted for infertility self-reported at
baseline; bPmpD antibody reactivity is based on a median cut-point; low reactivity <0.41, high reactivity ≥0.41; cPmpI antibody reactivity is based on a
median cut-point; low reactivity <0.89, high reactivity ≥0.89.
diﬀerences in PID progression. As PmpA, PmpD, and PmpI
have relatively low “oﬀ” frequencies (0.5–1%) [9], they
should be present for antigenic processing and presentation
allowing for antibody induction in the majority of infected
individuals. In fact, PmpD and PmpI antibodies were
frequent in our cohort. However, the prevalence of PmpA-
expressing inclusions in in vitro-grown C. trachomatis does
not correlate with the the low frequency of PmpA antibodies
detected in our cohort of women with clinical PID and in
other populations of C. trachomatis-infected patients [5].
The reason for this discrepancy is not entirely clear. Tan et al.
suggest that Pmp expression in in vitro-grown C. trachomatis
diﬀers from C. trachomatis in the human genital tract [9].
Chlamydiae processing and secretion of Pmp fragments may
also diﬀer, possibly resulting in varied antibody expression.
It is also possible that PmpA may have poor immunogenicity
or that PmpA antibodies were generated at low levels not
recognized by the initial SDS-PAGE analysis. Still, PmpA,
PmpD, and PmpI are the most conserved Pmps of C.
trachomatis, and their expression is unaltered in response to
stress [10]. This may suggest that PmpA, PmpD, and PmpI
are important for chlamydial survival and may play a role in
chlamydial pathogenesis [9, 10].
Not all women with PID go on to develop reproductive
morbidity. Studies havefoundalinkbetweentubalocclusion
and chlamydial antibodies [1, 19], as well as chlamydial
infection and post-PID infertility [1, 20]. Inﬂammation
caused by chlamydial infection may play a role in the
development of infertility, through damage to the cilia lining
of the Fallopian tubes, Fallopian tube blockage or closure,
or adhesion formation among pelvic organs [2]. Our data
indicate that women who express PmpA antibody were less
l i k e l yt oa c h i e v ep r e g n a n c ya n dl e s sl i k e l yt oh a v eal i v e
birth. Pregnancy and live birth can be used as markers
of fertility. These variables are easier to deﬁne compared
to infertility which requires classiﬁcation of contraception
than can be hampered by changing variables over time,
concurrent use of more than 1 method of contraception,
missing data, and compliance. Therefore, our results may
suggest that PmpA plays a role in upper genital tract
pathology. Although rates of inﬂammatory markers were
increased among women who express PmpA antibody, noInfectious Diseases in Obstetrics and Gynecology 7
statistically signiﬁcant diﬀerences were found between the
groups. These null ﬁndings could be a result of our limited
power. Due to the low frequency of PmpA in our cohort, we
were also unable to examine levels of antibody titer.
Data suggest that PmpD acts as an adhesion molecule
and stimulates proinﬂammatory cytokines through the
nuclear factor-κBp a t h w a y[ 7, 8]. Since PmpD may stim-
ulate host cell inﬂammatory responses, it is possible that
increased antibody to PmpD reﬂects increased exposure to
these potentially pathogenic ligands. We did ﬁnd increased
inﬂammation and reproductive sequelae among women
with high antibody titers to PmpD. However, these results
were nonsigniﬁcant. Overall, expression of PmpD antibody
appeared to have minimal eﬀects on inﬂammation and
reproductive sequelae in this study. Crane et al. reported that
anti-PmpD antibodies result in neutralization of chlamydial
elementary bodies and reduced infectivity in vitro [6]. In
our in vivo study, we found no evidence for protection from
disease in women with high seropositivity to PmpD. How-
ever, it should be noted that as our study used recombinant
denatured material for the measurement of seroreactivity,
in vivo antibody reactivity to native PmpD present on
chlamydial elementary bodies may not be fully reﬂected.
Tan et al. found that the PEACH PID population had
signiﬁcantly higher levels of PmpI antibodies compared to
adolescent females with lower genital tract infection (P<
0.0001) [5]. This could suggest that high titers to PmpI
could be associated with chlamydial progression to the
upper genital tract [10]. We did ﬁnd that women with
antibody reactivity to PmpI were more likely to have UGTI.
Endometritis was also more frequent in this group although
results were nonsigniﬁcant. When we examined PmpI as a
continuous variable, we did not ﬁnd a signiﬁcant diﬀerence
in PmpI antibody expression between women with UGTI
and women without UGTI. Therefore, this ﬁnding may have
been due to chance. Women from the PEACH cohort are
older and have likely been exposed to C. trachomatis more
often than adolescents. Screening studies have found that
older women have less infection but increased chlamydial
antibodies compared to adolescents [3]. Therefore, high
antibody reactivity to Pmps could represent a measure of
cumulativechlamydialexposure,indicatingthatwomenwith
more infections suﬀer greater sequelae. In fact, a study
among 443 PEACH participants found that PID recurrence
was higher (HR 2.48, 95% CI 1.00–6.27), and pregnancy
rates were signiﬁcantly lower (HR 0.47, 95% CI 0.28–
0.79) among women whose antibody titers to chlamydia EB
were in the highest tertile [21]. However, we were unable
to ﬁnd any signiﬁcant associations between high antibody
reactivity to PmpI or PmpD and reproductive sequelae.
Further, we found no signiﬁcant associations with markers
of inﬂammation.
There could be several reasons for our mostly null
ﬁndings. All women in our cohort had clinically suspected
PID. Therefore, we were unable to compare women with
chlamydial PID to women with uncomplicated C. tra-
chomatis infection. Future studies should compare these
groups to determine the role of Pmps in C. trachomatis
progression. In addition, our sample size limited our power
to detect signiﬁcant associations. We must also consider
other factors that may play a role in chlamydial pathogenesis.
It is possible that host susceptibility may explain why some
women with chlamydia experience sequelae and others do
not. In fact, chlamydia is suggested to be a disease of
immunopathology [3]. Therefore, genetic variations in host
immune receptors may cause unfavorable inﬂammation and
explain the variability in outcomes. Chlamydial load may
also play a role in the course and outcome of infection.
We did ﬁnd a borderline association with cervicitis among
women with high PmpD reactivity using logistic regression,
and chlamydial cervicitis has been associated with a higher
chlamydial load [22].
To our knowledge, this is the ﬁrst study to examine
the role of Pmp antibody response in inﬂammation and
post-PID sequelae. Data were obtained from a prospective
randomized clinical trial with comprehensive demographic,
clinical, and obstetric measurements. Further, our ﬁndings
are generalizable to patients treated for clinically suspected
PID. However, as some patients with clinically suspected
PID might actually have ovarian cysts, pelvic adhesions, or
endometriosis [23], some women in our study may not
have had true upper genital tract infection. We attempted
to minimize some of this misclassiﬁcation by excluding
women reporting greater than 30 days of pain at the time
of enrollment. We recognize that reproductive outcomes
were based on self-reported data and that misclassiﬁcation
bias is possible. Our analysis of Pmp seropositivity is
semiquantitative and cannot generate actual titers. However,
it is still suﬃcient for comparative rough estimates of Pmp-
subtype-speciﬁc titers. In addition, antibody expression may
diﬀer depending on the time course of the infection. We
are unable to conﬁrm when women ﬁrst became infected
with C. trachomatis. All women were recruited when they
presented for care for symptoms. We do know that time to
treatment does diﬀer among women with PID [24]. Time
to treatment did not signiﬁcantly diﬀer between any of our
groups. Serovars for C. trachomatis were not determined
in the PEACH study. However, PmpA, PmpD, and PmpI
are the most conserved Pmps of C. trachomatis, and it
is possible that their functions are also conserved across
serovars [9, 10]. As this pilot study is limited by power, larger
studies should continue to explore the role of Pmps in the
course and outcome of C. trachomatis infection. Speciﬁcally,
the correlation between PmpA antibody reactivity and
reproductive sequelae needs to be conﬁrmed.
Variabilityintheprogressionofchlamydialinfectionmay
be due to varied expression of chlamydial Pmps that are
reﬂected by the serum anti-Pmp antibody response. Our
data suggest that women who express PmpA antibody had
decreased pregnancy rates and decreased live births. Rates of
inﬂammatory markers were increased among women with
PmpA antibody although these results were nonsigniﬁcant.
In contrast, a positive antibody response to PmpD or PmpI
appeared to relate minimally to reproductive sequelae and
inﬂammation. Results were the same when high antibody
reactivity to both PmpD and PmpI was explored. These
results suggest a possible role for PmpA, but not for PmpD
or PmpI, in upper genital tract pathology.8 Infectious Diseases in Obstetrics and Gynecology
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